Drug-Eluting Stents (DES): A Comprehensive Guide for Cardiology

DES = Drug-Eluting Stent – a coronary or peripheral stent coated with an antiproliferative drug (sirolimus, everolimus, zotarolimus) embedded in a polymer matrix.

Mechanism

Local drug elution inhibits smooth muscle cell proliferation and migration, reducing neointimal hyperplasia and in-stent restenosis (ISR).

Generations

  • 1st gen: Cypher (sirolimus), Taxus (paclitaxel) – durable polymers, higher late thrombosis.
  • 2nd gen: Xience (everolimus), Promus – biocompatible polymers, thinner struts.
  • 3rd gen: Bioabsorbable polymer (Synergy, Orsiro) or polymer-free (BioFreedom) – improved healing.

Indications

  • Coronary artery disease (stable angina, ACS)
  • Peripheral artery disease (femoropopliteal, below-knee)

Key Consideration

Requires dual antiplatelet therapy (DAPT) (aspirin + P2Y12 inhibitor) for 6–12 months (per guidelines) to prevent stent thrombosis.

Cardiovascular Disease - Related Articles